NC
PCRX icon

Nicholas Company’s Pacira BioSciences PCRX Stock Holding History

Nicholas Company’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-169,745
Closed -$4.86M – 220
2024
Q2 		$4.86M Buy
169,745
+15,415
+10% +$439K 0.08% 192
2024
Q1 		$4.51M Hold
154,330
– – 0.07% 198
2023
Q4 		$5.21M Hold
154,330
– – 0.09% 192
2023
Q3 		$4.73M Hold
154,330
– – 0.09% 191
2023
Q2 		$6.18M Sell
154,330
-70
-0% -$2.89K 0.12% 171
2023
Q1 		$6.3M Buy
154,400
+11,690
+8% +$465K 0.13% 171
2022
Q4 		$5.51M Hold
142,710
– – 0.12% 178
2022
Q3 		$7.59M Hold
142,710
– – 0.17% 133
2022
Q2 		$8.32M Buy
142,710
+205
+0.1% +$13.4K 0.18% 130
2022
Q1 		$10.9M Hold
142,505
– – 0.19% 121
2021
Q4 		$8.57M Buy
142,505
+17,155
+14% +$946K 0.14% 165
2021
Q3 		$7.02M Buy
125,350
+10,015
+9% +$577K 0.12% 183
2021
Q2 		$7M Buy
115,335
+8,895
+8% +$563K 0.12% 190
2021
Q1 		$7.46M Sell
106,440
-50
-0% -$3.57K 0.14% 177
2020
Q4 		$6.37M Buy
+106,490
New +$6.24M 0.12% 188

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Nicholas Company's PCRX Position: Q3 2024 in Review

Nicholas Company sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 169,745 shares — an estimated $4.86M sold.

Nicholas Company first reported a position in PCRX in Q4 2020 and held it in 15 quarters. The position peaked at $10.9M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Nicholas Company reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Nicholas Company sold 169,745 Pacira BioSciences shares in Q3 2024, an estimated $4.86M.
  • Nicholas Company first reported a position in Pacira BioSciences in Q4 2020 and held it in 15 quarters.
  • Nicholas Company's Pacira BioSciences position peaked at $10.9M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Nicholas Company's 13F filing for Q3 2024, filed 12 Nov 2024.